Search

Your search keyword '"Han, Joseph K."' showing total 509 results
Start Over Author "Han, Joseph K."
509 results on '"Han, Joseph K."'

4. Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Author

Alsaleh, Saad, primary, Kamal, Nehal, additional, Hopkins, Claire, additional, Al Rand, Hussain, additional, Marglani, Osama A., additional, Alterki, Abdulmohsen, additional, Abu Suliman, Omar, additional, Alandejani, Talal, additional, Kamel, Reda, additional, Al Abri, Rashid, additional, Alotaibi, Naif H., additional, Al Amadi, Ahmad, additional, Bahakim, Abdullah, additional, Han, Joseph K., additional, Javer, Amin, additional, Sedaghat, Ahmad R., additional, and Gevaert, Philippe, additional

Published
2024
Full Text
View/download PDF

5. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial

Author

Emson, Claire, primary, Han, Joseph K., additional, Hopkins, Claire, additional, Asimus, Sara, additional, Cann, Jennifer A., additional, Chain, David, additional, Wu, Yuling, additional, Reddy, Yasa, additional, McCrae, Christopher, additional, Cohen, David, additional, Kreindler, James L., additional, Werkström, Viktoria, additional, Jison, Maria, additional, Wagenmann, Martin, additional, and Bachert, Claus, additional

Published
2024
Full Text
View/download PDF

6. Digital tools in allergy and respiratory care

Author

Verhoeven, Elisabeth, Rouadi, Philip, Jaoude, Eliane Abou, Abouzakouk, Mohamed, Ansotegui, Ignacio, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Azar, Cecilio, Bahna, Sami, Cuervo-Pardo, Lyda, Diamant, Zuzana, Douagui, Habib, Maximiliano Gómez, R., Díaz, Sandra González, Han, Joseph K., Idriss, Samar, Irani, Carla, Karam, Marilyn, Klimek, Ludger, Nsouli, Talal, Scadding, Glenis, Senior, Brent, Smith, Pete, Yáñez, Anahí, Zaitoun, Fares, and Hellings, Peter W.

Published
2022
Full Text
View/download PDF

10. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Ahlström Emanuelsson, Cecilia, Ardusso, Ledit, Armstrong, Michael, Bardin, Philip, Barnes, Sara, Bergna, Miguel, Betz, Christian, Beule, Achim, Blotter, James, Bronescu, Valeriu, Brown, Matthew, Carrie, Sean, Chaker, Adam, Cho, Hyung-Ju, Corriveau, Marie-Noëlle, Courville, Timothy, Cuevas, Mandy, Damask, Cecelia, DeConde, Adam, Del Carpio, Jaime, De Salvo, María, Dhong, Hun-Jong, Durham, Stephen, Edin, Anton, Ehmer Jr, Dale, Elías, Pedro, Fatakia, Adil, Franzese, Christine, Gane, Simon, García, Gabriel, Gillman, Andrew, Groeger, Moritz, Harvey, Richard, Hellgren, Johan, Higgins, Thomas, Hobson, Jonathan, Jangard, Mattias, Janjua, Arif, Kara, Naveed, Karpischenko, Sergey, Kerwin, Edward, Khanova, Fatimat, Kilty, Shaun, Kim, Chang-Hoon, Kim, Seontae, Klimek, Ludger, LaForce, Craig, Leong, Samuel, Marple, Bradley, Mårtensson, Anders, Maspero, Jorge, Massey, Neil, Matz, Jonathan, McDuffie, Chad, Mella, Corina, Miller, Steven, Mirzabekyan, Ekaterina, Moss, Jonathan, Mumneh, Nayla, Nathan, Robert, Neagos, Adriana, Olze, Heidi, Ovchinnikov, Andrey, Ow, Randall, Polyakov, Dmitriy, Radeanu, Doinel, Rhee, Chae-Seo, Rojas, Ramón, Rosenbloom, Jeffrey, Ryazantsev, Sergei, Sader, Chady, Saez Scherbovsky, Pablo, Scadding, Guy, Schlosser, Rodney, Shah-Patel, Heena, Shealy, Ronald, Siddiqi, Ayesha, Silvers, Stacey, Singh, Narinder, Sommer, Doron, Soong, Weily, Sowerby, Leigh, Spafford, Peter, Stefan, Catalin, Sterling, Richard, Svistushkin, Valeriy, Talreja, Neetu, Tarasova, Galina, Tarpay, Martha, Tolcachier, Alberto, Toll, Karin Toll, van Schaik, Carolina, Webb, Luke, Wedner, H James, Wehbe, Luis, Whan Kim, Soo, Wollenberg, Barbara, Wright, Simon, Yakusevich, Vladimir, Yañez, Anahí, Yarin, Yury, Yen, David, Yeol Kim, Hyo, Han, Joseph K, Bachert, Claus, Fokkens, Wytske, Desrosiers, Martin, Wagenmann, Martin, Lee, Stella E, Smith, Steven G, Martin, Neil, Mayer, Bhabita, Yancey, Steven W, Sousa, Ana R, Chan, Robert, and Hopkins, Claire

Published
2021
Full Text
View/download PDF

12. Ectopic Pituitary Adenomas Presenting as Sphenoid or Clival Lesions: Case Series and Management Recommendations

Author

Tajudeen, Bobby A, Kuan, Edward C, Adappa, Nithin D, Han, Joseph K, Chandra, Rakesh K, Palmer, James N, Kennedy, David W, Wang, Marilene B, and Suh, Jeffrey D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, Neurosciences, pituitary adenoma, ectopic pituitary tumors, sphenoid tumors, clival tumors, Neurology & Neurosurgery, Dentistry
Abstract

Background An ectopic pituitary adenoma presenting as a clival or sphenoid mass is a rare clinical occurrence that may mislead the clinician and result in unnecessary interventions or potential medicolegal consequences. Here, we present one of the largest multi-institutional case series and review the literature with an emphasis on radiological findings and critical preoperative workup. Methods Retrospective chart review. Results Nine patients were identified with ectopic pituitary adenomas of the sphenoid or clivus. There were four females and five males. Median age was 60 years old (range, 36-73 years). The most common presenting symptom was headache (56%). Five (56%) patients presented with a mass arising from the clivus while four (44%) presented with a mass in the sphenoid. Six (67%) patients demonstrated biochemical evidence of hypersecretion on full endocrinology panel. All masses showed evidence of enhancement with gadolinium with a propensity for adjacent bone involvement. Lesions also had a predilection for growth toward the cavernous sinus, carotid artery, or sellar floor. Surgical intervention was performed in eight patients (89%). In eight patients (89%), tumors demonstrated immunoreactivity to prolactin. Conclusions Pituitary adenomas can rarely present as an isolated sphenoid or clival mass. Lesions displayed similar magnetic resonance imaging findings with an erosive growth pattern toward the sellar floor, cavernous sinus, or adjacent carotid artery. Patients with clival or parasellar lesions with comparable features should have a preoperative workup which includes prolactin level and alert the physician to consider an ectopic pituitary adenoma in the differential to prevent unnecessary surgery and potential complications.

Published
2017

16. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.

Author

Hellings, Peter W., Alobid, Isam, Anselmo‐Lima, Wilma T., Bernal‐Sprekelsen, Manuel, Bjermer, Leif, Caulley, Lisa, Chaker, Adam, Constantinidis, Jannis, Conti, Diego M., De Corso, Eugenio, Desrosiers, Martin, Diamant, Zuzana, Gevaert, Philippe, Han, Joseph K., Heffler, Enrico, Hopkins, Claire, Landis, Basile N., Lourenco, Olga, Lund, Valerie, and Luong, Amber U.

Subjects
NASAL polyps, ENDOSCOPIC surgery, SINUSITIS, REOPERATION, PHYSICIANS, ASPIRIN
Abstract

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care

Author

Hellings, Peter W., primary, Alobid, Isam, additional, Anselmo‐Lima, Wilma T., additional, Bernal‐Sprekelsen, Manuel, additional, Bjermer, Leif, additional, Caulley, Lisa, additional, Chaker, Adam, additional, Constantinidis, Jannis, additional, Conti, Diego M., additional, De Corso, Eugenio, additional, Desrosiers, Martin, additional, Diamant, Zuzana, additional, Gevaert, Philippe, additional, Han, Joseph K., additional, Heffler, Enrico, additional, Hopkins, Claire, additional, Landis, Basile N., additional, Lourenco, Olga, additional, Lund, Valerie, additional, Luong, Amber U., additional, Mullol, Joaquim, additional, Peters, Anju, additional, Philpott, Carl, additional, Reitsma, Sietze, additional, Ryan, Dermot, additional, Scadding, Glenis, additional, Senior, Brent, additional, Tomazic, Peter Valentin, additional, Toskala, Elina, additional, Van Zele, Thibaut, additional, Viskens, An‐Sofie, additional, Wagenmann, Martin, additional, and Fokkens, W. J., additional

Published
2023
Full Text
View/download PDF

19. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Author

Laidlaw, Tanya M, primary, Menzies-Gow, Andrew, additional, Caveney, Scott, additional, Han, Joseph K, additional, Martin, Nicole, additional, Israel, Elliot, additional, Lee, Jason K, additional, Llanos, Jean-Pierre, additional, Martin, Neil, additional, Megally, Ayman, additional, Parikh, Bhavini, additional, Vong, Sylvia, additional, Welte, Tobias, additional, and Corren, Jonathan, additional

Published
2023
Full Text
View/download PDF

20. Evaluating treatment response to mepolizumab in patients with severe CRSwNP*

Author

Hopkins, Claire, Han, Joseph K., Lund, Valerie J., Bachert, Claus, Fokkens, Wytske J., Diamant, Zuzana, Mullol, Joaquim, Sousa, Ana R., Smith, Steven G., Yang, Shibing, Mayer, Bhabita, Yancey, Steve W., Chan, Robert H., and Lee, Stella E.

Subjects
nasal polyps, biological products, mepolizumab, systemic corticosteroid use, disease-specific quality of life
Abstract

Background: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP). Methods: SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS). Results: Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across ≥ 3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories). Conclusions: Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.

Published
2023

22. Clinical Consensus Statement

Author

Setzen, Gavin, Ferguson, Berrylin J, Han, Joseph K, Rhee, John S, Cornelius, Rebecca S, Froum, Stuart J, Gillman, Grant S, Houser, Steven M, Krakovitz, Paul R, Monfared, Ashkan, Palmer, James N, Rosbe, Kristina W, Setzen, Michael, and Patel, Milesh M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biomedical Imaging, Pediatric, Clinical Research, Humans, Paranasal Sinus Diseases, Tomography, X-Ray Computed, consensus statement, computed tomography, paranasal sinus disease, sinusitis, adults, children, Otorhinolaryngology, Clinical sciences
Abstract

ObjectiveTo develop a consensus statement on the appropriate use of computed tomography (CT) for paranasal sinus disease.Subjects and methodsA modified Delphi method was used to refine expert opinion and reach consensus by the panel.ResultsAfter 3 full Delphi rounds, 33 items reached consensus and 16 statements were dropped because of not reaching consensus or redundancy. The statements that reached consensus were grouped into 4 categories: pediatric sinusitis, medical management, surgical planning, and complication of sinusitis or sinonasal tumor. The panel unanimously agreed with 13 of the 33 statements. In addition, at least 75% of the panel strongly agreed with 14 of 33 statements across all of the categories.ConclusionsFor children, careful consideration should be taken when performing CT imaging but is needed in the setting of treatment failures and complications, either of the pathological process itself or as a result of iatrogenic (surgical) complications. For adults, imaging is necessary in surgical planning, for treatment of medical and surgical complications, and in all aspects of the complete management of patients with sinonasal and skull base pathology.

Published
2012

23. Clinical consensus statement: appropriate use of computed tomography for paranasal sinus disease.

Author

Setzen, Gavin, Ferguson, Berrylin J, Han, Joseph K, Rhee, John S, Cornelius, Rebecca S, Froum, Stuart J, Gillman, Grant S, Houser, Steven M, Krakovitz, Paul R, Monfared, Ashkan, Palmer, James N, Rosbe, Kristina W, Setzen, Michael, and Patel, Milesh M

Subjects
Humans, Paranasal Sinus Diseases, Tomography, X-Ray Computed, consensus statement, computed tomography, paranasal sinus disease, sinusitis, adults, children, Tomography, X-Ray Computed, Otorhinolaryngology, Clinical Sciences
Abstract

ObjectiveTo develop a consensus statement on the appropriate use of computed tomography (CT) for paranasal sinus disease.Subjects and methodsA modified Delphi method was used to refine expert opinion and reach consensus by the panel.ResultsAfter 3 full Delphi rounds, 33 items reached consensus and 16 statements were dropped because of not reaching consensus or redundancy. The statements that reached consensus were grouped into 4 categories: pediatric sinusitis, medical management, surgical planning, and complication of sinusitis or sinonasal tumor. The panel unanimously agreed with 13 of the 33 statements. In addition, at least 75% of the panel strongly agreed with 14 of 33 statements across all of the categories.ConclusionsFor children, careful consideration should be taken when performing CT imaging but is needed in the setting of treatment failures and complications, either of the pathological process itself or as a result of iatrogenic (surgical) complications. For adults, imaging is necessary in surgical planning, for treatment of medical and surgical complications, and in all aspects of the complete management of patients with sinonasal and skull base pathology.

Published
2012

26. Nasal disease with polyps: need for clarity

Author

Pezato, Rogerio, primary, Stamm, Aldo Cassol, additional, Douglas, Richard, additional, Han, Joseph K, additional, Chen, Philip G, additional, Neto, Carlos Diógenes Pinheiro, additional, Tepedino, Miguel Soares, additional, Singh, Narinder, additional, Balsalobre, Leonardo, additional, Ryu, Chang Hwan, additional, Gregório, Luciano, additional, Amatrafi, Sharif, additional, Felippu, Alexandre Wady Debes, additional, Iturriaga, Enrique, additional, Toledo, Ronaldo Nunes, additional, Cascio, Filippo, additional, Dassi, Camilla, additional, Alkholaiwi, Feras, additional, Bezerra, Thiago Freire Pinto, additional, Javer, Amin, additional, Dutra, Daniel Lorena, additional, Psaltis, Alkis James, additional, Migueis, Débora Petrungaro, additional, Almutari, Nasser, additional, Avelino, Melissa Ameloti Gomes, additional, Gunaratne, Dakshika Abeydeera, additional, Felippu, Alexandre, additional, Pinna, Fábio de Rezende, additional, Nakanishi, Márcio, additional, Perez‐Novo, Claudina A, additional, Singhera, Gurpreet K, additional, Choby, Garret, additional, Wang, Eric W, additional, Patel, Zara M, additional, and Thamboo, Andrew, additional

Published
2023
Full Text
View/download PDF

27. "Nasal Allergen Challenge (NAC): Practical Aspects and Applications from an EU/US perspective: A Workgroup Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee"

Author

Cho, Seong H, primary, Nanda, Anil, additional, Keswani, Anjeni, additional, Adinoff, Allen, additional, Baroody, Fuad M, additional, Bernstein, Jonathan A, additional, Gherasim, Alina, additional, Han, Joseph K, additional, Koepke, Jerald W, additional, Ledford, Dennis K, additional, Pepper, Amber N, additional, Rondón, Carmen, additional, Schiffman, Amy, additional, Wagenmann, Martin, additional, and Campo, Paloma, additional

Published
2023
Full Text
View/download PDF

28. Olfactory Outcomes with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps

Author

Mullol, Joaquim, Bachert, Claus, Amin, Nikhil, Desrosiers, Martin, Hellings, Peter W., Han, Joseph K., Jankowski, Roger, Vodička, Jan, Gevaert, Philippe, Daizadeh, Nadia, Khan, Asif H., Kamat, Siddhesh, Patel, Naimish, Graham, Neil M.H., Ruddy, Marcella, Staudinger, Heribert, Mannent, Leda P., Mullol, Joaquim, Bachert, Claus, Amin, Nikhil, Desrosiers, Martin, Hellings, Peter W., Han, Joseph K., Jankowski, Roger, Vodička, Jan, Gevaert, Philippe, Daizadeh, Nadia, Khan, Asif H., Kamat, Siddhesh, Patel, Naimish, Graham, Neil M.H., Ruddy, Marcella, Staudinger, Heribert, and Mannent, Leda P.

Abstract

BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 studies, adults with severe CRSwNP received dupilumab 300 mg subcutaneously or matching placebo every 2 weeks for 24 or 52 weeks, respectively. Smell was assessed using daily patient reported LoS score (0e3) and University of Pennsylvania Smell Identification Test (UPSIT; 0e40). Data from the 2 studies were pooled through week 24. Relationships between patient phenotypes and smell outcomes were also assessed. RESULTS: We randomized 724 patients (286 placebo, 438 dupilumab); mean CRSwNP duration was 11 years; 63% had prior sinonasal surgery. Mean baseline LoS was 2.74. Dupilumab produced rapid improvement in LoS, evident by day 3, which improved progressively throughout the study periods (least squares mean difference vs placebo L0.07 [95% CI L0.12 to L0.02]; nominal P < .05 at day 3, and L1.04 [L1.17 to L0.91]; P < .0001 at week 24). Dupilumab improved mean UPSIT by 10.54 (least squares mean difference vs placebo 10.57 [9.40e11.74]; P < .0001) at week 24 from baseline (score 13.90). Improvements were unaffected by CRSwNP duration, prior sinonasal surgery, or comorbid asthma and/or nonsteroidal anti-inflammatory drugeexacerbated respiratory disease. Baseline olfaction scores correlated with all measured local and systemic type 2 inflammatory markers except serum total immunoglobulin E. CONCLUSIONS: Dupilumab produced rapid and sustained improvement in sense of smell, alleviating a cardinal symptom of severe CRSwNP., Úvod: Ztráta čichu (LoS) je jednou z nejčastější problematicky a obtížně léčitelných příznaků těžké chronické rinosinusitidy s nosními polypy (CRSwNP). CÍL: Zhodnotit vliv Dupilumab na čich u těžké CRSwNP. METODY: V randomizovaných SINUS-24 a SINUS-52 studiích dostávali dospělí s těžkým CRSwNP Dupilumab 300 mg subkutánně nebo odpovídající placebo každé 2 týdny po dobu 24 nebo 52 týdnů. Čich byl hodnocen pomocí denního skóre LoS hlášeného pacientem (0e3) a testu identifikace University of Pennsylvania (UPSIT; 0e40). Údaje ze dvou studií byly shromážděny do týdne 24. Vztahy mezi pacienty byly také hodnoceny fenotypy a výsledky čichových testů. METODY: V randomizovaných SINUS-24 a SINUS-52 studiích dostávali dospělí s těžkým CRSwNP Dupilumab 300 mg subkutánně nebo odpovídající placebo každé 2 týdny po dobu 24 nebo 52 týdnů. Čich byl hodnocen pomocí denního skóre LoS hlášeného pacientem (0e3) a testu identifikace University of Pennsylvania (UPSIT; 0e40). Údaje ze 2 studií byly shromážděny do týdne 24. Byly také hodnoceny vztahy mezi fenotypy pacientů a výsledky čichových testů. VÝSLEDKY: Randomizovali jsme 724 pacientů (286 placebo, 438 Dupilumab); průměrná doba trvání CRSwNP byla 11 let; 63 % mělo předchozí sinonazální chirurgii. Průměrná výchozí hodnota LoS byla 2,74. Dupilumab způsobil rychlé zlepšení LoS, patrné do 3. dne, což se progresivně zlepšovalo v průběhu období studie (průměrný rozdíl oproti placebu L0,07 [95% CI L0,12 až L0,02]; nominální P < 0,05 v den 3 a L1,04 [L1,17 až L0,91]; P < 0,0001 v týdnu 24). Dupilumab zlepšil průměrný výsledek UPSIT o 10,54 (průměrný rozdíl oproti placebu 10,57 [9,40e11,74]; P < 0,0001) ve 24. týdnu od výchozího stavu (skóre 13,90). Zlepšení nebylo ovlivněné trváním CRSwNP, předchozí sinonazální operací, popř. komorbidním astma a/nebo nesteroidní protizánětlivé, lékově exacerbované respirační onemocnění. Základní skóre čichu korelovalo se všemi naměřenými lokálními a systémovými zánětlivými markery 2. typu, kromě celko

Published
2023

29. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Author

Laidlaw,Tanya M, Menzies-Gow,Andrew, Caveney,Scott, Han,Joseph K, Martin,Nicole, Israel,Elliot, Lee,Jason K, Llanos,Jean-Pierre, Martin,Neil, Megally,Ayman, Parikh,Bhavini, Vong,Sylvia, Welte,Tobias, Corren,Jonathan, Laidlaw,Tanya M, Menzies-Gow,Andrew, Caveney,Scott, Han,Joseph K, Martin,Nicole, Israel,Elliot, Lee,Jason K, Llanos,Jean-Pierre, Martin,Neil, Megally,Ayman, Parikh,Bhavini, Vong,Sylvia, Welte,Tobias, and Corren,Jonathan

Abstract

Laidlaw TM, Menzies-Gow A, Caveney S, et al. J Asthma Allergy. 2023;16:915–932. The authors have advised there is an error in Figure 1 on page 922. The n= x-axis data were transposed for the treatment groups for both the Patients with NPs and Patients without NPs. The correct Figure 1 is as follows. Figure 1 AAER over 52 weeks in patients with or without nasal polyps in the 2 years before randomization in the NAVIGATOR study.Abbreviations: AAER, annualized asthma exacerbation rate; CI, confidence interval; NP, nasal polyp; Q4W, every 4 weeks.Note: n, number of patients contributing to the analysis. The authors apologize for this error.

Published
2023

30. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

Author

Laidlaw,Tanya M, Menzies-Gow,Andrew, Caveney,Scott, Han,Joseph K, Martin,Nicole, Israel,Elliot, Lee,Jason K, Llanos,Jean-Pierre, Martin,Neil, Megally,Ayman, Parikh,Bhavini, Vong,Sylvia, Welte,Tobias, Corren,Jonathan, Laidlaw,Tanya M, Menzies-Gow,Andrew, Caveney,Scott, Han,Joseph K, Martin,Nicole, Israel,Elliot, Lee,Jason K, Llanos,Jean-Pierre, Martin,Neil, Megally,Ayman, Parikh,Bhavini, Vong,Sylvia, Welte,Tobias, and Corren,Jonathan

Abstract

Tanya M Laidlaw1,2 &ast;, Andrew Menzies-Gow3 &ast;, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan Corren17 1Jeff and Penny Vinik Center for Allergic Diseases Research, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Medicine, Harvard Medical School, Boston, MA, USA; 3Royal Brompton and Harefield Hospitals, School of Immunology and Microbial Sciences, King’s College London, London, UK; 4Global Development, Inflammation, R&D, Amgen, Thousand Oaks, CA, USA; 5Department of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA; 6Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA; 7Cytel Inc, Waltham, MA, USA; 8Divisions of Pulmonary and Critical Care Medicine and Allergy and Clinical Immunology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 9Evidence Based Medical Educator Inc., Toronto, ON, Canada; 10Toronto Allergy and Asthma Clinic, Toronto, ON, Canada; 11Global Medical Affairs, Amgen, Thousand Oaks, CA, USA; 12Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 13University of Leicester, Leicester, UK; 14Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; 15Translational Science and Experimental Medicine, Early Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA; 16Department of Respiratory Medicine and German Center for Lung Research, Hannover Medical School, Hannover, Germany; 17David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA&ast;These authors contributed equally to this workCorrespondence: Tanya M Laidlaw, Jeff and Penny Vinik Center for Allergic

Published
2023

31. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Author

Fokkens, W. J., Viskens, An Sofie, Backer, Vibeke, Conti, Diego, de Corso, Eugenio, Gevaert, Philippe, Scadding, Glenis K., Wagemann, Martin, Sprekelsen, Manuel Bernal, Chaker, Adam, Heffler, Enrico, Han, Joseph K., Staeyen, Elizabeth Van, Hopkins, Claire, Mullol, Joaquim, Peters, Anju, Reitsma, Sietze, Senior, Brent A., Hellings, Peter W., Fokkens, W. J., Viskens, An Sofie, Backer, Vibeke, Conti, Diego, de Corso, Eugenio, Gevaert, Philippe, Scadding, Glenis K., Wagemann, Martin, Sprekelsen, Manuel Bernal, Chaker, Adam, Heffler, Enrico, Han, Joseph K., Staeyen, Elizabeth Van, Hopkins, Claire, Mullol, Joaquim, Peters, Anju, Reitsma, Sietze, Senior, Brent A., and Hellings, Peter W.

Abstract

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

Published
2023

35. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps

Author

Siddiqui, Shahid, primary, Bachert, Claus, additional, Chaker, Adam M., additional, Han, Joseph K., additional, Hellings, Peter W., additional, Peters, Anju T., additional, Heffler, Enrico, additional, Kamat, Siddhesh, additional, Zhang, Haixin, additional, Nash, Scott, additional, Khan, Asif H., additional, De Prado Gomez, Lucia, additional, Jacob-Nara, Juby A., additional, Rowe, Paul J., additional, and Deniz, Yamo, additional

Published
2022
Full Text
View/download PDF

38. Indications for absorbable steroid‐eluting sinus implants: Viewpoint via the Delphi method

Author

Lee, Victoria S., primary, Patel, Prayag, additional, O'Brien, Daniel, additional, Scangas, George A., additional, Campbell, Raewyn G., additional, Chandra, Rakesh, additional, Davis, Greg E., additional, Han, Joseph K, additional, Le, Christopher H., additional, Lee, Jivianne, additional, Luong, Amber U., additional, Poetker, David M., additional, Ramadan, Hassan, additional, Setzen, Michael, additional, Smith, Kristine, additional, Wise, Sarah, additional, Villwock, Jennifer, additional, and Ference, Elisabeth, additional

Published
2022
Full Text
View/download PDF

42. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count

Author

Bachert, Claus, primary, Sousa, Ana R., additional, Han, Joseph K., additional, Schlosser, Rodney J., additional, Sowerby, Leigh J., additional, Hopkins, Claire, additional, Maspero, Jorge F., additional, Smith, Steven G., additional, Kante, Oliver, additional, Karidi-Andrioti, Despina E., additional, Mayer, Bhabita, additional, Chan, Robert H., additional, Yancey, Steve W., additional, and Chaker, Adam M., additional

Published
2022
Full Text
View/download PDF

43. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps

Author

Gevaert, Philippe, Han, Joseph K., Smith, Steven G., Sousa, Ana R, Howarth, Peter H., W Yancey, Steven, Chan, Robert, and Bachert, Claus

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is generally associated with eosinophilic tissue infiltration linked to type 2 inflammation and characterized by elevated levels of interleukin (IL)-5 and other type 2 inflammatory mediators. Although distinct and overlapping contributions of eosinophils and IL-5 to CRSwNP pathology are still being explored, they are both known to play an important role in NP inflammation. Eosinophils secrete numerous type 2 inflammatory mediators including granule proteins, enzymes, cytokines, chemokines, growth factors, lipids, and oxidative products. IL-5 is critical for the differentiation, migration, activation, and survival of eosinophils but is also implicated in the biological functions of mast cells, basophils, innate lymphoid cells, B cells, and epithelial cells. Results from clinical trials of therapeutics that target type 2 inflammatory mediators (including but not limited to anti-IL-5, anti-immunoglobulin-E, and anti-IL-4/13) may provide further evidence of how eosinophils and IL-5 contribute to CRSwNP. Finally, the association between eosinophilia/elevated IL-5 and greater rates of NP recurrence after endoscopic sinus surgery (ESS) suggests that these mediators may have utility as biomarkers of NP recurrence in diagnosing and assessing the severity of CRSwNP. This review provides an overview of eosinophil and IL-5 biology and explores the literature regarding the role of these mediators in CRSwNP pathogenesis and NP recurrence following ESS. Based on current published evidence, we suggest that although eosinophils play a key role in CRSwNP pathophysiology, IL-5, a cytokine that activates these cells, also represents a pertinent and effective treatment target in patients with CRSwNP.

Published
2022

44. Nasal Nitric Oxide as a Biomarker in the Diagnosis and Treatment of Sinonasal Inflammatory Diseases: A Review of the Literature.

Author

Benedict, Jacob J., Lelegren, Matthew, Han, Joseph K., and Lam, Kent

Subjects
RHINITIS treatment, SINUSITIS treatment, BIOMARKERS, ONLINE information services, NASAL polyps, PARANASAL sinus diseases, CHRONIC diseases, SYSTEMATIC reviews, RHINITIS, SINUSITIS, RESEARCH funding, NITRIC oxide, MEDLINE, ACUTE diseases
Abstract

Objective: To critically review the literature on nasal nitric oxide (nNO) and its current clinical and research applicability in the diagnosis and treatment of different sinonasal inflammatory diseases, including acute bacterial rhinosinusitis (ABRS), allergic rhinitis (AR), and chronic rhinosinusitis (CRS). Methods: A search of the PubMed database was conducted to include articles on nNO and sinonasal diseases from January 2003 to January 2020. All article titles and abstracts were reviewed to assess their relevance to nNO and ABRS, AR, or CRS. After selection of the manuscripts, full-text reviews were performed to synthesize current understandings of nNO and its applications to the various sinonasal inflammatory diseases. Results: A total of 79 relevant studies from an initial 559 articles were identified using our focused search and review criteria. nNO has been consistently shown to be decreased in ABRS and CRS, especially in cases with nasal polyps. While AR is associated with elevations in nNO, nNO levels have also been found to be lower in AR cases with higher symptom severity. The obstruction of the paranasal sinuses is speculated to be an important variable in the relationship between nNO and the sinonasal diseases. Treatment of these diseases appears to affect nNO through the reduction of inflammatory disease burden and also mitigation of sinus obstruction. Conclusion: nNO has been of increasing interest to researchers and clinicians over the last decade. The most compelling data for nNO as a clinical tool involve CRS. nNO can be used as a marker of ostiomeatal complex patency. Variations in measurement techniques and technology continue to impede standardized interpretation and implementation of nNO as a biomarker for sinonasal inflammatory diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

Author

Bachert, Claus, primary, Han, Joseph K., additional, Desrosiers, Martin Y., additional, Gevaert, Philippe, additional, Heffler, Enrico, additional, Hopkins, Claire, additional, Tversky, Jody R., additional, Barker, Peter, additional, Cohen, David, additional, Emson, Claire, additional, Martin, Ubaldo J., additional, Shih, Vivian H., additional, Necander, Sofia, additional, Kreindler, James L., additional, Jison, Maria, additional, and Werkström, Viktoria, additional

Published
2022
Full Text
View/download PDF

49. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study

Author

Gevaert, Philippe, primary, Saenz, Rebecca, additional, Corren, Jonathan, additional, Han, Joseph K., additional, Mullol, Joaquim, additional, Lee, Stella E., additional, Ow, Randall A., additional, Zhao, Rui, additional, Howard, Monet, additional, Wong, Kit, additional, Islam, Lutaf, additional, Ligueros-Saylan, Monica, additional, Omachi, Theodore A., additional, and Bachert, Claus, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results